The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA575948
Title Identification of Prostate Cancer Prognostic Markers.
Publication Date Oct 2012
Media Count 7p
Personal Author J. Lapointe
Abstract The objective of this project is to develop prognostic markers for prostate cancer and identify potential therapeutic targets. The specific aims are: (1) To profile bone metastasis samples to identify genomic alterations of prostate cancer metastases that can be retrieved in their corresponding primary tumors, (2) To evaluate the prognostic value of specific genomic alterations in localized primary tumors with clinical follow-up database, (3) To ascertain the relevance to disease progression of genes residing in genomic alterations of prostate cancer metastases. Progress has been made in the three aims. Extraction of nucleic acid and microarray profiling of small samples has been optimized to carry out AIM1 experiments. The FISH probes to be used in AIM2 have been generated and their specificity confirmed. Preliminary analysis indicates that at least one of our biomarkers of interest would predict prostate cancer recurrence. Toward AIM3, a V5-tagged GABARAPL2 expression vector has been constructed which allow its ectopic expression in prostate cancer cells. Two siRNAs were able to knockdown the ectopic expression of GABARAPL2 in prostate cancer cell line PC-3. These tools will serve for the functional studies of AIM3. Overall, the work accomplished shall lead to the realisation of the objective of this project.
Keywords Acids
Bones
Canada
Cdna cloning
Clinical medicine
Diseases
Ectopic expression
Fishes
Fluorescence in situ hybridization (Fish)
Foreign reports
Gene silencing
Genomic alteration
Identification
Metastasis
Neoplasms
Probes
Prognostic markers
Prostate cancer
Prostate cancer cell lines
Sampling
Targets


 
Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author McGill Univ., Montreal (Quebec). Health Center.
Document Type Technical report
Title Note Annual rept. 30 Sep 2011-29 Sep 2012.
NTIS Issue Number 1319
Contract Number W81XWH-11-1-0638

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader